Comparison of lipidomic profiles sampled with electroporation-based biopsy from healthy skin, squamous cell carcinoma, and basal cell carcinoma

Incidence rates of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are increasing, while the current diagnostic process is time consuming. We introduce a high-throughput sampling approach, termed e-biopsy, utilizing electroporation-based biopsy for efficient collection of tissue lipids. Our study identified 168 lipids using ultra-performance liquid chromatography and tandem mass spectrometry (UPLC-MS-MS). The e-biopsy technique demonstrated its ability to profile the human skin lipidome. Comparative analysis revealed 27 differentially expressed lipids (p<0.05). The observed trend of lipidomic profiles was low diglycerides in cSCC and BCC, elevated phospholipids in BCC, and increased lyso-phospholipids in cSCC compared to healthy skin samples. These findings contribute to understanding skin cancers and highlight the potential of e-biopsy for lipidomic analysis in skin tissues. ### Competing Interest Statement EV, AS, JW, AG, ZY are consultants to Elsy Medical. ### Funding Statement The authors thank Israel Innovation authority Kamin project, the TAU SPARK fund, TAU Zimin Center for technologies for better life and the EuroNanoMed MATISSE project for their support of this project. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Meir Medical Center IRB, number MMC-19-0230. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript and supplementary material. [https://github.com/GolbergLab/BCC\_SCC\_Lipidomics][1]. * BCC : basal cell carcinoma Cer : ceramides CerG2 : diglycosylceramide cSCC : cutaneous squamous cell carcinoma DG : diglyceride e-biopsy : electroporation-based biopsy LPC : lyso-phosphatidylcholine LPE : lyso-phosphatidylethanolamine LPI : lyso-phosphatidylinositol PC : phosphatidylcholine PI : phosphatidylinositol PS : phosphatidylserine TG : triglyceride UPLC-MS-MS : ultra performance liquid chromatography and tandem mass spectrometry [1]: https://github.com/GolbergLab/BCC_SCC_Lipidomics